Abstracts tagged "Cardiovascular disease"

Abstract Number: 1405 • 2014 ACR/ARHP Annual Meeting
Five-Year Changes in Myocardial Structure and Function in Patients with Rheumatoid Arthritis
John M. Davis III¹, Grace Lin², Jae Oh³, Cynthia S. Crowson⁴, Terry M. Therneau⁵, Eric L. Matteson¹ and Sherine E. Gabriel⁶, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Cardiology, Mayo Clinic, Rochester, MN, ³Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer an increased risk of heart failure not explained by traditional cardiovascular risk factors. Previously, we have shown…
Abstract Number: 898 • 2014 ACR/ARHP Annual Meeting
Traditional Cardiovascular Risk-Factor Management in Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients in a US Managed Care Setting
J An¹, K Reynolds², E Alemao³, H Kawabata³, D H Solomon⁴, K P Liao⁵ and T C Cheetham², ¹Western University of Health Sciences, Pomona, CA, ²Kaiser Permanente Southern California, Pasadena, CA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Studies have suggested suboptimal care of traditional cardiovascular risk factors (CRF) in patients (pts) with RA as a reason for elevated CV risk compared…
Abstract Number: 354 • 2014 ACR/ARHP Annual Meeting
Increased Vascular Wall Inflammation in Patients with Active Rheumatoid Arthritis As Measured By an 18F-FDG-PET/CT Scan
Rabia Agca^1,2, Alper M. van Sijl^2,3, Yvo M. Smulders⁴, Alexandre E. Voskuyl⁵, Connie J. van der Laken⁶, Ronald Boellaard⁷, Karel-Jan D.F. Lensen⁸ and Michael T. Nurmohamed^1,2, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²VU University Medical Center, Amsterdam, Netherlands, ³[email protected], Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Internal Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁸Department of Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose : Patients with rheumatoid arthritis (RA) have an elevated risk of developing cardiovascular disease (CVD). Like active RA, atherosclerosis is an inflammatory process. There…
Abstract Number: 2829 • 2014 ACR/ARHP Annual Meeting
Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
Nigil Haroon¹, Nisha Nigil Haroon², Ping Li³, Michael Paterson³ and Robert D. Inman⁴, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose OnSpA is a population-based study of spondyloarthritis (SpA) based on a provincial population of over 13 million. Patients with SpA are thought to be…
Abstract Number: 1913 • 2014 ACR/ARHP Annual Meeting
Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases
Silvia Rollefstad¹, Eirik Ikdahl¹, Jonny Hisdal², Inge C. Olsen³, Ingar Holme⁴, Hilde Berner Hammer⁵, Knut T. Smerud⁶, G Kitas⁷, Terje R. Pedersen⁸, Tore K. Kvien⁹ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Uslo University Hospital-Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of biostatistics, epidemiology and health economics, Oslo University Hospital, Oslo, Norway, ⁵Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁶Smerud Medical Research International AS, Oslo, Norway, ⁷The Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ⁸Faculty of Medicine, University of Oslo, Oslo, Norway, ⁹PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose Patients with rheumatoid arthritis (RA) and carotid artery plaques (CP) have increased risk of acute coronary syndromes. Statin treatment with low density lipoprotein cholesterol…
Abstract Number: 1390 • 2014 ACR/ARHP Annual Meeting
Heterogeneity in Cardiovascular Risk Factors, Event Rates and RA Disease Characteristics Among Patients with Rheumatoid Arthritis Across 10 Countries – Implications for CV Risk Assessment
Atacc-RA Collaborative Group, Division of Rheumatology, Mayo Clinic, Rochester, MN; Diakonhjemmet hospital, Oslo, Norway; Dudley Group NHS Foundation Trust, West Midlands, United Kingdom; Radboud University Medical Center, Nijmegen, Netherlands; University of Umeå, Umeå, Sweden; University of Athens, Athens, Greece; Harbor UCLA Medical Center, Torrance, CA; Harvard Medical School Brigham and Women's Hospital, Boston, MA; Hospital Universitario Marques de Valdecilla, Santander, Spain; School of Physiology, Faculty of Health Sciences, Witwatersrand University, Johannesburg, South Africa; University of Manitoba, Winnipeg, MB, Canada; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubir, México City, Mexico; Hospital Medisch Spectrum Twente, Enschede, Netherlands
Background/Purpose Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD). CVD risk scores for the general population do not accurately predict…
Abstract Number: 842 • 2014 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jie Zhang¹, Shuo Yang², Lang Chen³, Fenglong Xie⁴, Huifeng Yun⁵, Paul M. Muntner⁶, Emily Levitan⁶, Monica Safford⁷, Kenneth G. Saag⁸, Jasvinder A. Singh⁷ and Jeffrey R. Curtis⁷, ¹Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Recently cholesterol treatment guidelines recommend that diabetes (DM) should be considered a CVD risk equivalent to a history of coronary heart disease (CHD). Despite…
Abstract Number: 341 • 2014 ACR/ARHP Annual Meeting
Death Receptor 3 Causes Vascular Dysfunction in a Murine Model of Rheumatoid Arthritis
Jessica O Williams¹, Eddie C.Y. Wang², Derek Lang¹ and Anwen S. Williams², ¹Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Increased cardiovascular (CV) risk is prevalent in several forms of inflammatory arthritides. The mechanisms that regulate CV disease during early inflammatory arthritis are ill-defined.…
Abstract Number: 2641 • 2014 ACR/ARHP Annual Meeting
Cardiac Magnetic Resonance Imaging in Systemic Lupus Erythematosus
Alexa Meara¹, Namrata Dhillon², Kimberly Fisher³, Paul Jensen⁴ and Stacy P. Ardoin⁵, ¹Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Internal Medicine/Pediatrics, The Ohio State University, Nationwide Children's Hospital, Columbus, OH, ⁵Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose Cardiac complications of SLE are common and include both acute and chronic manifestations: pericarditis, myocarditis, valvular disease, pulmonary hypertension, atherosclerosis, ischemic and non-ischemic cardiomyopathy. …
Abstract Number: 1909 • 2014 ACR/ARHP Annual Meeting
Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Alper van Sijl¹, Mamas Mamas², Mark Lunt^3,4, . BSRBR Control Centre Consortium³, Kath Watson⁵, Deborah P. Symmons^3,6 and Kimme L. Hyrich⁷, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK; Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease compared to the general population, with an increased incidence…
Abstract Number: 1400 • 2014 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolic Events in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies
Michelle Avina¹, Sally Choi², Sharan Rai³, Hyon K. Choi⁴ and Mary De Vera^3,5, ¹Faculty of Sciences, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Boston University School of Medicine, Boston, MA, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common vascular event after myocardial infarction…
Abstract Number: 841 • 2014 ACR/ARHP Annual Meeting
Lipid Control and Cardiovascular Risk for Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients
J An¹, E Alemao², K Reynolds³, H Kawabata², D H Solomon⁴, K P Liao⁴ and T C Cheetham³, ¹Western University of Health Sciences, Pomona, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Kaiser Permanente Southern California, Pasadena, CA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Lipid levels are known to be lower in patients with RA compared with the general population; however, differences in cardiovascular (CV) risk associated with…
Abstract Number: 337 • 2014 ACR/ARHP Annual Meeting
Effect of Etanercept on Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis
Perle Totoson¹, Katy Maguin-Gaté¹, Daniel Wendling² and Céline Demougeot¹, ¹EA 4267 « Fonctions et Dysfonctions Epithéliales » , Faculté de Médecine-Pharmacie, Besançon, France, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose Growing evidence indicate that Rheumatoid Arthritis (RA)-associated increase in cardiovascular risk is secondary to the presence of endothelial dysfunction (ED). Although Tumor Necrosis Factor…
Abstract Number: 2828 • 2013 ACR/ARHP Annual Meeting
The Performance Of The Original and An Updated Cardiovascular Risk Algorithm (SCORE) In Patients With Rheumatoid Arthritis
Elke.E.A. Arts¹, Calin Popa¹, Alfons A. den Broeder², Anne Grete Semb³, Tracey Toms⁴, George Kitas⁴, Piet L.C.M. van Riel¹ and Jaap Fransen¹, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, United Kingdom
Background/Purpose: Cardiovascular (CV) risk in rheumatoid arthritis (RA) is increased. The CV risk algorithms for the general population may underestimate the risk of cardiovascular disease…
Abstract Number: 1709 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Cardiovascular Disease Prevention Experiences: Qualitative Analysis and Implications
Christie M. Bartels¹, Sarah Tweddell², Barbara Bowers³, Elizabeth Jacobs⁴ and Tonya Roberts³, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW School of Medicine and Public Health, Madison, WI, ³UW School of Nursing, Madison, WI, ⁴Internal Medicine, UW School of Medicine and Public Health, Madison, WI
Background/Purpose: Although rheumatoid arthritis (RA) increases cardiovascular disease (CVD) risk, RA patients receive less CVD preventive care than peers. We previously showed gaps in lipid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].